Record tools

Copy identifiers or export this single peptide record for a local research note.

PEPDIA-INT-021088

Silver

Bivalirudin

Quality

Source DBs

Activities

Source refs

Literature

Patents

Integrated record

Sequence and molecular profile

FPRPGGGGNGDFEEIPEEYL

Indexed sequence20 aa

1FPRPGGGGNGDFEEIPEEYL

Length

Molecular weight

2180.32 Da

Formula

C98H138N24O33

Structure type

Linear

Synthesis

Chirality

Family

Gene

Residue composition

Physicochemical profile

Hydrophobic5

Membrane affinity proxy

Polar1

Solubility proxy

Charged6

Net charge proxy -4

Aromatic3

Binding interaction proxy

Versioned scientific descriptors

Physicochemical properties and standard representations

calculated sequence and structure

Reported properties

Legacy compatibility fields are materialized from the versioned PepDiana computed release; no separate source-reported property is available.

Computed properties

physchem-20260620

Molecular weight

2180.2851 Da

Molecular formula

C98H138N24O33

Theoretical pI

4.05

Net charge at pH 7

-4.2285

GRAVY

-0.985

Instability index

77.45

Aromaticity

0.15

Topological polar surface area

901.57 Å²

cLogP

-8.1164

Hydrogen-bond donors

Hydrogen-bond acceptors

Rotatable bonds

Method: PepDiana sequence/structure descriptor pipeline

Tool: Biopython+RDKit · Biopython 1.85; RDKit 2024.09.6

Calculated: 2026-06-20T11:01:38.358971+00:00

Assumptions: ph=7; termini=free N-terminus and free C-terminus for simple linear peptides; stereochemistry=standard L-amino acids; smiles_length_limit=200

Sequence representations

representations-20260620 · RDKit 2024.09.6

ProForma 2.0

validated simple linear

FPRPGGGGNGDFEEIPEEYL

HELM 2.0

validated simple linear

PEPTIDE1{F.P.R.P.G.G.G.G.N.G.D.F.E.E.I.P.E.E.Y.L}$$$$V2.0

Canonical SMILES

validated

CCC(C)C(NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(Cc1ccccc1)NC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)C1CCCN1C(=O)C(CCCNC(=N)N)NC(=O)C1CCCN1C(=O)C(N)Cc1ccccc1)C(=O)N1CCCC1C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1ccc(O)cc1)C(=O)NC(CC(C)C)C(=O)O

Isomeric SMILES

validated

CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)O

Follow-up research

External analysis tools

Run BLASTPSearch similar protein or peptide sequences at NCBI.Search UniProtLook for related UniProtKB entries using the sequence.Search PubMedFind literature context for this peptide record.Search PubChemOpen chemistry search with the canonical SMILES string.

Links open third-party resources with the current PepDiana sequence, record name, or chemistry notation as the initial query.

Research workflow

Citation and local history

BibTeX

@misc{PEPDIA-INT-021088,
  title = {Bivalirudin},
  author = {{PepDiana Consortium}},
  year = {2026},
  howpublished = {PepDiana Multifunctional Peptide Database},
  url = {http://127.0.0.1:3004/peptides/PEPDIA-INT-021088},
  note = {Accessed from local PepDiana development build}
}

APA-style note

Bivalirudin. (2026). PepDiana record PEPDIA-INT-021088. PepDiana Multifunctional Peptide Database. http://127.0.0.1:3004/peptides/PEPDIA-INT-021088

This record is saved to local recent-view history so it can reappear on the peptide browser page.

Integrated source-database annotations

Biological activity (7 records)

Stable record	Activity	Subtype	Value	Target	Assay method	Source
CTPDB_P021088_ACT_peptherdia_0000	Clinical / Approved Drug	General Therapeutic	Not available in the current structured import	Unknown	Not reported by source	9peptherdia / linked
CTPDB_P021088_ACT_thpdb_0001	Clinical / Approved Drug	General Therapeutic	Not available in the current structured import	Unknown	Not reported by source	Th1006_10032_rec0thpdb / unavailable
CTPDB_P021088_ACT_thpdb_0002	Clinical / Approved Drug	General Therapeutic	Not available in the current structured import	Unknown	Not reported by source	Th1006_10033_rec1thpdb / unavailable
CTPDB_P021088_ACT_thpdb_0003	Clinical / Approved Drug	General Therapeutic	Not available in the current structured import	Unknown	Not reported by source	Th1006_10034_rec2thpdb / unavailable
CTPDB_P021088_ACT_thpdb_0004	Clinical / Approved Drug	General Therapeutic	Not available in the current structured import	Unknown	Not reported by source	Th1006_10035_rec3thpdb / unavailable
CTPDB_P021088_ACT_thpdb_0005	Clinical / Approved Drug	General Therapeutic	Not available in the current structured import	Unknown	Not reported by source	Th1006_10036_rec4thpdb / unavailable
CTPDB_P021088_ACT_thpdb_0006	Clinical / Approved Drug	General Therapeutic	Not available in the current structured import	Unknown	Not reported by source	Th1006_10037_rec5thpdb / unavailable

Provenance

Source database records (7)

Source-specific sequence or modification context. One or more source records use a sequence notation that differs from the canonical backbone. Open each raw sequence before interpreting stereochemistry, terminal groups, or non-standard residues.

peptherdia

Raw sequence

fPRPGGGGNGDFEEIPEEYL

thpdb

Th1006_10032_rec0

Raw sequence

FPRPGGGGNGDFEEIPEEYL

thpdb

Th1006_10033_rec1

Raw sequence

FPRPGGGGNGDFEEIPEEYL

thpdb

Th1006_10034_rec2

Raw sequence

FPRPGGGGNGDFEEIPEEYL

thpdb

Th1006_10035_rec3

Raw sequence

FPRPGGGGNGDFEEIPEEYL

thpdb

Th1006_10036_rec4

Raw sequence

FPRPGGGGNGDFEEIPEEYL

thpdb

Th1006_10037_rec5

Raw sequence

FPRPGGGGNGDFEEIPEEYL

Citation trail

Literature (1 records)

[{"text": "drugbank.com", "url": "https://go.drugbank.com/drugs/DB00006", "markdown": "[drugbank.com](https://go.drugbank.com/drugs/DB00006)"}, {"text": "medicines.org.uk", "url": "https://www.medicines.org.uk/emc/product/7229/smpc#gref", "markdown": "[medicines.org.uk](https://www.medicines.org.uk/emc/product/7229/smpc#gref)"}, {"text": "fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20873lbl.pdf", "markdown": "[fda.gov](https://www.accessdata.fda.gov/drugsatfda_doc

[{"text": "drugbank.com", "url": "https://go.drugbank.com/drugs/DB00006", "markdown": "[drugbank.com](https://go.drugbank.com/drugs/DB00006)"}, {"text": "medicines.org.uk", "url": "https://www.medicines.org.uk/emc/product/7229/smpc#gref", "markdown": "[medicines.org.uk](https://www.medicines.org.uk/emc/product/7229/smpc#gref)"}, {"text": "fda.gov", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20873lbl.pdf", "markdown": "[fda.gov](https://www.accessdata.fda.gov/drugsatfda_doc

Audit surface

Raw annotations and release metadata

Integrated record last updated: 2026-04-15T00:59:21.345173+00:00

Modification summary

No structured modification annotations are available for this record.

ADMET

{
  "toxicity": [
    {
      "source_db": "thpdb",
      "assay_method": "Based on a study by Gleason et al., the no observed adverse effect level (NOAEL) for bivalirudin administered to rats via Intravenous infusion over a 24-hour period, was 2000 mg/kg/24 h.",
      "toxicity_type": "Toxicity"
    },
    {
      "source_db": "thpdb",
      "assay_method": "Based on a study by Gleason et al., the no observed adverse effect level (NOAEL) for bivalirudin administered to rats via Intravenous infusion over a 24-hour period, was 2000 mg/kg/24 h.",
      "toxicity_type": "Toxicity"
    },
    {
      "source_db": "thpdb",
      "assay_method": "Based on a study by Gleason et al., the no observed adverse effect level (NOAEL) for bivalirudin administered to rats via Intravenous infusion over a 24-hour period, was 2000 mg/kg/24 h.",
      "toxicity_type": "Toxicity"
    },
    {
      "source_db": "thpdb",
      "assay_method": "Based on a study by Gleason et al., the no observed adverse effect level (NOAEL) for bivalirudin administered to rats via Intravenous infusion over a 24-hour period, was 2000 mg/kg/24 h.",
      "toxicity_type": "Toxicity"
    },
    {
      "source_db": "thpdb",
      "assay_method": "Based on a study by Gleason et al., the no observed adverse effect level (NOAEL) for bivalirudin administered to rats via Intravenous infusion over a 24-hour period, was 2000 mg/kg/24 h.",
      "toxicity_type": "Toxicity"
    },
    {
      "source_db": "thpdb",
      "assay_method": "Based on a study by Gleason et al., the no observed adverse effect level (NOAEL) for bivalirudin administered to rats via Intravenous infusion over a 24-hour period, was 2000 mg/kg/24 h.",
      "toxicity_type": "Toxicity"
    }
  ]
}

Source metadata

[
  {
    "source_db": "peptherdia",
    "organism_name": "Unknown"
  },
  {
    "source_db": "thpdb",
    "organism_name": "Unknown"
  }
]

Clinical trials

[
  {
    "status": "Therapeutic",
    "drug_name": "Bivalirudin",
    "source_db": "peptherdia",
    "indication": "For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.",
    "approval_year": 2000,
    "approval_agency": "FDA",
    "administration_route": "IV, IC"
  }
]

Approved drug annotations

{
  "status": "Therapeutic",
  "drug_name": "Bivalirudin",
  "source_db": "peptherdia",
  "indication": "For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.",
  "approval_year": 2000,
  "approval_agency": "FDA",
  "administration_route": "IV, IC"
}